Mechanical ventilation for bone marrow transplant patients: when does it become futile?

H. Klingemann

DOI: https://doi.org/10.1097/00003246-200003000-00057

IF: 8.8

2000-03-01

Critical Care Medicine

Abstract:The first bone marrow transplants were performed in the early 1970s in patients who had treatment-resistant endstage leukemia. The fact that some of these patients are still alive is a testimony to the underlying certainty that bone marrow transplants can lead to long-term survival, and possibly cure, in patients with otherwise fatal hematologic diseases. During the last two decades, it has become clear that transplantation at an earlier stage, when the disease is in remission, results in long-term survival of ~50% to 70% among transplant recipients depending on the type of disease they have (1). Prolonged chemotherapy administered before transplantation is the most significant risk factor for posttransplant complications (2). Since the early days of transplantation, the development of more effective immunosuppressive drugs and supportive care has made possible a reduction in the transplant-related mortality to 2% to 3% for autologous and 15% to 20% for allogeneic matched-sibling transplant recipients.